¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"blood group specific substance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • specific activity
    1. ºñ¹æ»ç´É 2. ºñ(Ýï)Ȱ¼ºµµ, °íÀ¯È°¼ºµµ
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • specific antigen
    ƯÀÌÇ׿ø
  • specific capsular reaction
    ƯÀÌÇǸ·¹ÝÀÀ
  • specific charge
    ºñÀüÇÏ, °ßÁÜÀüÇÏ
  • specific compliance
    ºñ¼øÀÀµµ
  • specific conductivity
    ºñÀüµµÀ²
  • specific death rate
    ƯÀÌ»ç¸Á·ü
  • specific electric conductivity
    ºñÀü±âÀüµµÀ²
  • specific fertility rate
    ƯÀÌ»ý½Ä·ü, ºñ»ý½Ä·ü
  • specific granule
    ƯÀ̰ú¸³
  • specific gravity
    ºñÁß
  • specific gravity test
    ºñÁß°Ë»ç
  • specific growth rate
    ƯÀÌÁõ½Ä·ü, ƯÀ̼ºÀå·ü
  • specific heat
    ºñ¿­(Ýïæð)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • index group
    ÃʹßȯÀÚ±º
  • labile methyl group
    ºÒ¾ÈÁ¤¸ÞÆ¿±â
  • linkage group
    ¿¬°ü±º
  • marathon group
    ¸¶¶óÅæÁý´Ü
  • methyl group
    ¸ÞÆ¿±â
  • minority group
    ¼Ò¼öÁý´Ü
  • nonionic polar group
    ºñÀ̿±ؼº±â
  • open group
    °ø°³Áý´Ü, °³¹æÁý´Ü
  • osmophore group
    ¹ßÇâ´Ü
  • prosthetic group
    ¹èÇÕ±º
  • self-help group
    ÀÚÁ¶Áý´Ü
  • soluble group
    °¡¿ëÇØ±º
  • symmetry group
    ´ëαº
  • taxonomic group
    ºÐ·ùÁý´Ü
  • topological group
    À§»ó±º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Manson blood fluke
    ¸¸¼ÕÇ÷ÈíÃæ
  • OMNISTIK blood gas syringe
    ¿È´Ï½ºÆ½Ç÷¾×°¡½ºÁÖ»ç±â
  • RBC=£¾red blood cell
    ÀûÇ÷±¸.
  • Schaedler blood agar
    ¼¨µé·¯Ç÷¾×ÇÑõ
  • accessory blood vessel
    ºÎÇ÷°ü, Á¾¼ÓÇ÷°ü
  • arterial blood
    µ¿¸ÆÇ÷.
  • arterial blood gas
    µ¿¸ÆÇ÷°¡½º
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • arterial blood oxygen tension
    µ¿¸ÆÇ÷»ê¼Ò Àå·Â.
  • arterial blood pressure
    µ¿¸ÆÇ÷¾Ð.
  • artificial blood
    ÀΰøÇ÷¾×
  • artificial blood vessel
    ÀΰøÇ÷°ü(¡­Ç÷°ü).
  • artificial blood vessel
    ÀΰøÇ÷°ü(¡­úìη).
  • fragility of blood
    ÀûÇ÷±¸ÆÄ±«¼º.
  • fresh whole blood
    ½Å¼±ÀüÇ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • marathon group
    ¸¶¶óÅæÁý´Ü
  • methyl group
    ¸ÞÆ¿±â.
  • minority group
    ¼Ò¼ö±×·ì.
  • nonionic polar group
    ºñÀ̿±ؼº±â.
  • open group
    °ø°³Áý´Ü(˭˧̤ËÀ), °³¹æÁý´Ü (˧ËÑ̤ËÀ).
  • osmophore group
    ¹ßÇâ´Ü(Û¡úÅÓ¥).
  • permutation group
    ġȯ?öÇüµÏØ).
  • permutation group
    ġȯ±º(̷̬˴).
  • permutation group
    ġȯ±º(öÇüµÏØ).
  • posterior group of aphasia
    ÈĺνǾ(ý­Ý»ã÷åÞÏØ).
  • posterior group of aphasia
    ÈĺνǾ(ý­Ý»ã÷åÞÏØ)
  • prepaid group practice
    ¼±ºÒÁ¦Áý´Ü°³¿ø.
  • prostheitc group
    ¹èÇÕ±º(ÛÕùêÏØ).
  • prosthetic group-labeled enzyme
    º¸Á¶±ºÇ¥ÁöÈ¿¼Ò
  • prosthetic group-labeled immunoassay
    º¸Á¶±ºÇ¥Áö¸é¿ªÃøÁ¤(¹ý)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • glycolyl group
    ±Û¶óÀÌÄÚ¸±±â(Ðñ)
  • glycosyl group
    ±Û¶óÀÌÄڽDZâ(Ðñ)
  • Gm group
    Gm ±â(Ðñ)
  • group specificity
    ±â(Ðñ) ƯÀ̼º(÷åì¶àõ)
  • group transfer reaction
    ¿øÀÚ´Ü ÀüÀÌ ¹ÝÀÀ(ê«í­Ó¥ï®ì¹Úãëë)
  • group transfer potential
    ¿øÀÚ´Ü ÀüÀÌ ÀüÀ§(ê«í­Ó¥ï®ì¹Úãëë)
  • group translocation
    ¹«¸® ÀüÀ§(ï®êÈ)
  • guanidinium group
    ±¸¾Æ´Ïµð´Ï¿ò±â(Ðñ)
  • guanidino group
    ±¸¾Æ´Ïµð³ë±â(Ðñ)
  • guanido group
    ±¸¾Æ´Ïµµ±â(Ðñ)
  • haptenic group
    ÇÕÅÙ±â(Ðñ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • hydroxymethyl group
    ÇÏÀ̵å·Ï½Ã¸ÞÆ¿±â(Ðñ)
  • hypsochromic group
    û»öÀ̵¿±â(ôìßäì¹ÔÑÐñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
MBF medullary blood flow; muscle blood flow; myocardial blood flow
NRBC National Rare Blood Club; normal red blood cell; nucleated red blood cell
RBC red blood cell; red blood corpuscle; red blood count
WBC well baby care/clinic; white blood cell; white blood cell count; whole blood cell count
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
MIS Muellerian inhibiting substance
PSUD Psychoactive Substance Use Disorder
"RCS" Rabbit aorta Contracting Substance
SRS-A Slow Reacting Substance of Anaphylaxis
SRS Slow reacting substance
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood agar
    Ç÷¾× ÇÑõ
  • blood alcohol level
    Ç÷Áß ¾ËÄÚ¿Ã ³óµµ
  • blood blister
    ¼ÒÇ÷Á¾
    Ç÷¾×¼º ³»¿ë¹°À» °¡Áø ÀÛÀº ¼öÆ÷·Î¼­ ²¿ÁýÈ÷°Å³ª Ÿ¹Ú»óÀ¸·Î »ý±âÁö¸¸ °¡²û Áö¼ÓÀûÀÎ ¸¶Âû¿¡ ÀÇÇØ¼­µµ »ý±ä´Ù.
  • blood capillary
    ¸ð¼¼Ç÷°ü
    ¼Òµ¿¸Æ°ú ¼ÒÁ¤¸ÆÀ» ¿¬°áÇÏ´Â ¹Ì¼¼ÇÑ Ç÷°ü. ÀÌ º®Àº Ç÷¾×°ú Á¶Á÷¾×ÀÇ ¿©·Á ¹°ÁúÀ» ±³È¯Çϱâ À§ÇÑ ¹ÝÅõ¸·À¸·Î ÀÛ¿ëÇÑ´Ù.
  • blood cell counter
    Ç÷±¸ °è¼ö±â
  • blood center
    Ç÷¾×¿ø
    µ¿ÀǾî=blood transfusion service. ¼öÇ÷¿¡ ÇÊ¿äÇÑ Ç÷¾×À» äÇ÷, Á¶Á¦, º¸Á¸ÇÏ°í °ø±ÞÇÏ´Â ±â°ü. 1937³â ¹Ì±¹ ½ÃÄ«°íÀÇ ÄîÄ«¿îƼ
  • blood cerebrospinal fluid barrier
    Ç÷³ú ô¼ö¾× À庮, Ç÷¾× ³úô¼ö¾× °ü¹®
  • blood circulation
    Ç÷¾× ¼øÈ¯
    Á½ɽǿ¡¼­ µ¿¸ÆÀ¸·Î ¾ÐÃâµÈ Ç÷¾×Àº ¸ð¼¼Ç÷°üÀ» °ÅÃļ­ Á¤¸ÆÀ¸·Î ³ª¿À°í ¿ì½É¹æÀ¸·Î ȯ·ùÇØ À̰÷¿¡¼­ ¿ì½É½Ç·Î µé¾î°£´Ù. ¿ì½É½ÇÀÇ ¼öÃàÀ¸·Î Æóµ¿¸ÆÀ¸·Î º¸³»Á® Æó ¸ð¼¼°üÀ» °ÅÃļ­ Æó Á¤¸Æ¿¡¼­ Á½ɹæÀ¸·Î µé¾î°¡°í ´Ù½Ã Á½ɽǷΠµé¾î°¡ ¸ö ¾ÈÀ» ÇѹÙÄû µ·´Ù.
  • blood clotting disturbance
    Ç÷¾× ÀÀ°í Àå¾Ö
  • blood coagulation
    Ç÷¾× ÀÀ°í
    µ¿ÀǾî=blood clotting. 1. Ç÷¾×ÀÇ ¸¹Àº ÀÀ°íÀÎÀÚ°¡ »óÈ£ÀÛ¿ëÇϰí ÇÕÃÄÁ®¼­ ÃÖÈÄ¿¡´Â ºÒ¿ë¼ºÀÇ ¼¶À¯¼Ò ±«ÀÇ Çü¼ºÀ» ÀÏÀ¸Å°´Â ¿¬¼ÓÀû ¹ÝÀÀÀÌ´Ù. 2. Ç÷¾×ÀÌ Ç÷°ü ¹ÛÀ¸·Î ³ª¿ÔÀ» ¶§ Á©¸®»óÀ¸·Î ±»¾îÁö´Â Çö»ó. À̰ÍÀº Ç÷¾× ¼Ó¿¡ ÇǺ기À̶ó°í ÇÏ´Â ½Ç ¸ð¾çÀÇ ¹°ÁúÀÌ ¼®ÃâµÇ¾î ±×¹° ¸ð¾çÀ¸·Î ¾ôÈ÷°í, ±× ¼Ó¿¡ Ç÷±¸¸¦ °¡µÎ¾î µÎ±â ¶§¹®ÀÌ´Ù. ÀÌ Ç÷±¸ µ¢¾î¸®´Â ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Á¡Á¡ ¼öÃàÇÏ¿© ÀÛ¾ÆÁö¸é¼­ ´ãȲ»öÀÇ Åõ¸íÇÑ ¾×ü°¡ ½º¸ç ³ª¿Â´Ù. Ç÷±¸ÀÇ µ¢¾î¸®¸¦ Ç÷º´À̶ó Çϰí, ½º¸ç ³ª¿Â Åõ¸íÇÑ ¾×ü¸¦ Ç÷ûÀ̶ó°í ÇÑ´Ù. Ç÷¾× ÀÀ°í´Â »ý¸íÀ» À¯ÁöÇÏ´Â µ¥ ºÒ°¡°áÇÑ °ÍÀ¸·Î, ¸¸ÀÏ Ç÷¾×¿¡ ÀÌ ÀÛ¿ëÀÌ ¾øÀ¸¸é ÃâÇ÷¿¡ ÀÇÇÏ¿© °ð Á×°Ô µÈ´Ù. ÀÏ»ó»ýȰ¿¡¼­´Â ²÷ÀÓ¾øÀÌ ¿Ü»óÀ» ÀÔ°Ô µÇ°í ±×¶§ ´Ù¼Ò³ª¸¶ ¸ð¼¼Ç÷°üÀÌ ÆÄ¿­µÇ´Âµ¥, ÆÄ¼ÕºÎÀ§´Â Ç÷¾× ÀÀ°í¿¡ ÀÇÇÏ¿© ¼öº¹µÈ´Ù. Ç÷¾× ÀÀ°í°¡ ÀϾ´Â ¸ÞÄ¿´ÏÁò¿¡ ´ëÇØ¼­´Â ¸î °¡Áö ¼³ÀÌ ÀÖÁö¸¸ ¾î´À °ÍÀÌµç ±âº»ÀûÀ¸·Î´Â Ç÷¾×ÀÌ Ç÷°ü ¹ÛÀ¸·Î ³ª¿À¸é Ç÷¼ÒÆÇÀÌ ÆÄ±«µÇ¾î Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ »ý±â°í, À̰ÍÀÌ Ç÷¾× ¼ÓÀÇ Ä®½· À̿°ú ÇÔ²² ÀÛ¿ëÇÏ¿© Ç÷Àå ´Ü¹éÁúÀÇ ÇϳªÀÎ ÇÁ·ÎÆ®·ÒºóÀ» Æ®·ÒºóÀ¸·Î º¯È­½ÃŲ´Ù. ÀÌ Æ®·ÒºóÀÌ ÇǺ긮³ë°Õ¿¡ ÀÛ¿ëÇÏ¿© ÇǺ기ÀÌ µÈ´Ù. ÀÌ °úÁ¤¿¡´Â Ç÷ÀåÀ̳ª Ç÷¼ÒÆÇ¿¡ ÀÖ´Â ¸¹Àº ÀÎÀÚ°¡ °ü¿©Çϴµ¥, ¿¬±¸ÀÚ¿¡ µû¶ó °¢¾ç°¢»öÀÇ À̸§À¸·Î ºÒ¸®¾î È¥¶õÀ» ÃÊ·¡Çϰí ÀÖÀ¸¹Ç·Î, ±¹Á¦Ç÷¾×ÀÀ°íÀ§¿øÈ¸¿¡¼­ À̵é ÀÎÀÚ¸¦ ¹øÈ£·Î ³ªÅ¸³»µµ·Ï °áÁ¤Çϰí ÀÖ´Ù. Á¦1»óÀÇ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ Çü¼ºµÇ´Â °úÁ¤ÀÌ °¡Àå º¹ÀâÇϰí, Ç÷¾× ÀÀ°í¿¡ °É¸®´Â ´ëºÎºÐÀÇ ½Ã°£ÀÌ ÀÌ °úÁ¤¿¡ ¼Ò¿äµÈ´Ù. Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ ¸¸µé¾îÁö´Â µ¥´Â µÎ °¡Áö °æ·Î°¡ ÀÖ´Ù. óÀ½ °æ·Î´Â Ç÷°ü ¼Ó¿¡¼­ ÀÌ·ç¾îÁø´Ù. Ç÷Àå ¼Ó¿¡ À̹°Áú°ú Á¢Çϸé Ȱ¼ºÈ­µÇ´Â È¿¼Ò°¡ Àִµ¥, ÇöÀç Á¦ XIÀÎÀÚ¿Í Á¦ XIIÀÎÀÚÀÇ µÎ °¡Áö°¡ ¾Ë·ÁÁ® ÀÖ´Ù. À̰ÍÀÌ ¹æ¾Æ¼è°¡ µÇ¾î Á¦ VÀÎÀÚ, Á¦ VIIIÀÎÀÚ, Á¦ IXÀÎÀÚ µî°ú Ç÷¼ÒÆÇÀ¸·ÎºÎÅÍÀÇ ÀÎÀÚ°¡ ÀÛ¿ëÇÏ¿© Ç÷¾× Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ »ý¼ºµÈ´Ù. ´Ù¸¥ ÇϳªÀÇ °æ·Î´Â Ç÷°ü ¹ÛÀÇ Á¶Á÷¿¡¼­ ÀÌ·ç¾îÁø´Ù. ÆÄ±«µÈ Á¶Á÷¿¡ Ç÷Àå ¼ÓÀÇ Á¦ VÀÎÀÚ, Á¦ VIIÀÎÀÚ, Á¦ XÀÎÀÚ µîÀÌ ÀÛ¿ëÇÏ¿© Á¶Á÷ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ »ý¼ºµÈ´Ù. Á¦2»óÀÇ Æ®·ÒºóÀÇ »ý¼º¿¡¼­´Â Ç÷¾× ¹× Á¶Á÷¿¡ »ý±ä Ȱ¼º Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÌ Ä®½· À̿°ú ÇÔ²² Ç÷Àå ¼ÓÀÇ ÇÁ·ÎÆ®·Òºó¿¡ ÀÛ¿ëÇÏ¿© Æ®·ÒºóÀ» Çü¼ºÇÑ´Ù. ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼­ ºñŸ¹Î KÀÇ ÀÛ¿ëÇÏ¿¡ ¸¸µé¾îÁö°í, ÇìÆÄ¸°Àº ÀÌ Á¦ 2»óÀ» ¾ïÁ¦ÇÏ¿© Ç÷¾× ÀÀ°í ÀúÁö ÀÛ¿ëÀ» ³ªÅ¸³½´Ù. Á¦ 3»ó¿¡¼­´Â Æ®·ÒºóÀÌ ÇǺ긮³ë°ÕÀÇ ÆéƼµå °áÇÕÀ» ºÐÇØÇÏ¿© ÇǺ기 ¼¶À¯¸¦ ¼®Ãâ½ÃŲ´Ù. ¿©±â¿¡ Ä®½· À̿°ú ÇÔ²² Á¦ XIII ÀÎÀÚ°¡ ÀÛ¿ëÇÏ¿© ÇǺ기¸ÁÀ» ¸¸µé¾î Ç÷º´ÀÌ ¿Ï¼ºµÈ´Ù. ¿©±â¿¡¼­ »ý¼ºµÈ ÇǺ기Àº ±×´ë·Î µÎ¸é ´Ù½Ã ¿ëÇØµÇ´Âµ¥ À̰ÍÀ» ¼¶À¯¼Ò ¿ëÇØ¶ó°í ÇÑ´Ù. ÀÌ ¼¶À¯¼Ò ¿ëÇØ´Â Ç÷Àå ¼Ó¿¡ ÀÖ´Â Çö󽺹̳ë°ÕÀÌ È°¼ºÈ­ÇÏ¿© Çö󽺹ÎÀÌ µÇ°í ÇǺ기À» ³ìÀ̱⠶§¹®ÀÌ´Ù.
  • blood compatibility testing
    Ç÷¾× ÀûÇÕ¼º °Ë»ç
  • blood concentration
    Ç÷Áß ³óµµ
  • blood count
    Ç÷±¸°è»ê
    ÀÏÁ¤ÀÇ Ç÷¾×·® 1§§Áß À¯Çü ¼ººÐ¼öÀÇ ÃøÁ¤.
  • blood culture
    Ç÷¾× ¹è¾ç
  • blood disease
    Ç÷¾× ÀÌ»ó
    µ¿ÀǾî=hemic disease.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
zymoplastic substance <haematology> Traditional name for substance in plasma that converts prothrombin to thrombin. Now known not to be a single substance. (See thrombin).
(18 Nov 1997)
filar substance A filamentous plasmatic material, beaded with granules, demonstrable by means of vital staining in the immature red blood cells.
Synonym: alpha substance, filar mass, filar substance, substantia reticularis, substantia reticulofilamentosa.
Synonym: reticular formation.
(05 Mar 2000)
age-specific rate A rate for a specified age group, in which the numerator and denominator refer to the same age group.
(05 Mar 2000)
Bensley's specific granules Granule's in the cells of the islands of Langerhans in the pancreas.
(05 Mar 2000)
brain-specific kinase <enzyme> Expressed specifically in brain; member of the eph/elk receptor-like kinase family; mw 105 kD; may represent murine homolog of chicken cek7 receptor-like kinase; amino acid sequence given in first source
Registry number: EC 2.7.1.-
Synonym: bsk tyrosine kinase
(26 Jun 1999)
galactosyl-1-3-N-acetylgalactosaminyl-specific 2,6-sialyltransferase <enzyme> Genbank x77775
Registry number: EC 2.4.99.-
Synonym: galbeta1,3galnac 2,6-sialyltransferase, st6galnac II
(26 Jun 1999)
glycoprotein hormone-specific N-acetylgalactosamine transferase <enzyme> Transfers galnac to the terminal glcnac moieties of glcnac2man3glcnac2asn
Registry number: EC 2.4.1.-
Synonym: ghs-acgalnh2 transferase, glycoprotein hormone galnac transferase, glycoprotein hormone - n-acetylgalactosaminyltransferase
(26 Jun 1999)
retina-specific amine oxidase <enzyme> Genbank d88213
Registry number: EC 1.4.-
Synonym: rao enzyme, human
(26 Jun 1999)
Gomori's non-specific acid phosphatase stain <technique> A method in which formalin-fixed frozen sections are incubated in a substrate containing sodium beta-glycerophosphate and lead nitrate at pH 5.0; the insoluble lead phosphate produced is treated with ammonium sulfide to give a black lead sulfide.
(05 Mar 2000)
Gomori's non-specific alkaline phosphatase stain <technique> A calcium-cobalt sulfide method using frozen sections or cold acetone-or formalin-fixed paraffin sections, plus sodium beta-glycerophosphate as a substrate at pH 9.0 to 9.5 with Mg++ as activator; calcium ions precipitate the liberated phosphate, cobalt salt replaces the calcium phosphate, and ammonium sulfide converts the product to a black cobalt sulfide.
(05 Mar 2000)
RNA, transfer, amino acid-specific A group of transfer rnas which are specific for carrying each one of the 20 amino acids to the ribosome in preparation for protein synthesis.
(12 Dec 1998)
poly A specific exoribonuclease <enzyme> Acts on 2' or 3'-linked oligoriboadenylates to liberate 5'-AMP
Registry number: EC 3.1.13.-
Synonym: 2',3'-exoribonuclease, 3'-exoribonuclease
(26 Jun 1999)
poly(A)-specific ribonuclease <enzyme> From vigna unguiculata seedlings; bifunctional enzyme responsible for both poly(a)-polymerizing and poly(a)-hydrolyzing activities; removes the poly(a) tail as the first step in degrading mRNA
Registry number: EC 3.1.13.4
Synonym: poly(a) nuclease, mRNA poly(a) nuclease, poly(a) ribonuclease (pan), pan2 protein
(26 Jun 1999)
myelencephalon-specific serine protease <enzyme> Specifically expressed in the nervous system; plays a role in normal homeostasis and response of spinal cord to injury.
Registry number: EC 3.4.21.-
Synonym: myelencephalon-specific protease, msp enzyme
(26 Jun 1999)
pregnancy-specific beta 1-glycoprotein A glycoprotein with the electrophoretic mobility of a beta-1 globulin. It is produced by the placental trophoblast and secreted into the maternal bloodstream during pregnancy. It can be detected 18 days after ovulation and its concentration in plasma rises steadily until, at the end of gestation, it reaches 200 mg/ml. It has been proposed as a measure of placental function for fertility control and is a candidate for an early pregnancy test.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á